SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report

Tropical Medicine and Infectious Disease

Bruna Provenci¹  Sandrigo Mangini¹  SarahCristina Gozzi-Silva²  DanielleRosa Beserra²  FrancianeMouradian Emidio Teixeira²  AnnaCláudia Calvielli Castelo Branco²  IaraGrigoletto Fernandes²  NátalliZanete Pereira²  AnnaJulia Pietrobon²  EmilyAraujo de Oliveira²  MariaNotomi Sato²  Gil Benard²  YasmimÁlefe Leuzzi Ramos²  RicardoWesley Alberca²  AlbertoJosé da Silva Duarte²  Luanade Mendonça Oliveira²  JuliaCataldo Lima²  TatianaMina Yendo²  MilenaMary de Souza Andrade² 

[1] Instituto do Coração (Incor), Hospital das Clínicas, School of Medicine of University of São Paulo (HCFMUSP), 05403-900 São Paulo, Brazil;Laboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil;

关键词: SARS-CoV-2;    COVID-19;    heart transplant;    CMV;    Chagas disease;    infection;   

DOI  :  10.3390/tropicalmed6010022

来源: DOAJ

【 摘 要 】

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a pandemic. SARS-CoV-2 infection can lead to severe pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and/or organ failure. Individuals receiving a heart transplantation (HT) may be at higher risk of adverse outcomes attributable to COVID-19 due to immunosuppressives, as well as concomitant infections that may also influence the prognoses. Herein, we describe the first report of two cases of HT recipients with concomitant infections by SARS-CoV-2, Trypanosoma cruzi, and cytomegalovirus (CMV) dissemination, from the first day of hospitalization due to COVID-19 in the intensive care unit (ICU) until the death of the patients.

【 授权许可】

Unknown